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INTRODUCTION
The majority of mortality studies in patients with RA published since 1950 have shown an increased mortality from cardiovascular disease (CVD) (1) . There is now intense interest in verifying and quantifying this excess CVD risk and understanding the underlying mechanisms.
Most previous mortality studies examined cohorts of patients with established RA (2) (3) (4) . This may cause selection bias towards more severe progressive disease and left censorship. The study of inception cohorts of RA patients is less likely to reveal decreased survival rates because of the potential to include patients with milder disease (5) . Several recently reported mortality studies, (6) (7) (8) (9) (10) (11) , have followed patients from early in their RA disease process. Four of these studies (7) (8) (9) failed to identify any increased mortality rates in RA patients with disease onset during the 1980s-90s. One study showed that mortality rates from acute myocardial infarction declined in patients with RA onset in more recent decades (11) . Possible explanations for the relative improvement in RA patient survival include the earlier introduction of disease modifying therapy (8;9) , or a change in the natural history of RA (7) with the disease becoming less severe over recent years (12) . It is possible that excess mortality in these RA cohorts may be identified with continued long-term follow-up (13) .
However, excess mortality from CVD was observed in a primary care based cohort of patients with early seropositive inflammatory arthritis (10) . Data from the Mayo clinic also suggest that the excess mortality associated with RA did not fall during the 1980s-90s (14) . A study of RA patients identified from the Swedish Hospital discharge register reported that, although mortality rates fell towards the end of the last century, mortality from coronary heart disease remained particularly high in RA patients (15) .Thus it is difficult to know whether the survival prospects of RA patients have changed in recent years. Long term follow up of RA inception cohorts is required.
One possible explanation for the excess CVD mortality in RA is an increased prevalence of comorbid CVD. Studies in the US have shown that RA patients have higher rates of CVD events than in the general population (16;17) and describe CVD comorbidity more frequently in RA than OA patients (18) . However, there have also been reports that RA patients are more likely to experience silent ischaemic heart disease and sudden cardiac death than the general population (19) . An alternative explanation for the increased CVD mortality in RA could be that these patients have an increased case fatality rate from CVD events.
Aims

1)
To examine whether RA patients with disease onset in the 1980s-1990s, identified in a hospital clinic setting, have increased mortality compared to the local general population. 2) To compare cardiovascular admission rates in RA patients with those of the general population.
METHODS
Setting
Stockport is a large urban area, south of Manchester, UK with a population of nearly 285,000. 
Stockport RA register
This inception cohort of 1,010 RA patients was identified from a register of all newly diagnosed RA patients, based on consultant rheumatologist's opinion, attending Stockport rheumatology out-patient clinics between 1981 and 1996. Patients were designated seropositive if, at the time of diagnosis, they had either an IgM rheumatoid factor (RF) titre of 1:40 or above, or rheumatoid nodules. Many of these patients were subsequently discharged from regular rheumatology follow up. Thus, unlike many previously described hospital based cohorts (2;20-24) , the Stockport RA cohort is composed of patients with a broad spectrum of RA disease severity and is not restricted to those under long-term rheumatology follow-up.
MORTALITY STUDY
Patients and methods
Identification data including NHS numbers, names, dates of birth and last known address were sent to the Office for National Statistics (ONS) for flagging and notification of deaths using the National Health Service Central Register (NHSCR) (25) . ONS were able to match 979 (97%) of the 1,010 patients and provided death drafts for all patients who died prior to 31 st December 2002. The causes of death were coded according to WHO rules using ICD-9 until the 1 st Jan 2001 when ICD-10 coding was introduced.
The Stockport district population was used as the reference group for calculating Standardised Mortality Ratios (SMRs). ONS provided mortality rates for all causes, cardiovascular causes, respiratory causes and neoplasia, for men and women separately in 10-year age bands, for the years 1982-2001. Population death rates for the year 2002 were not available at the time of analysis and cohort mortality rates in this year were compared with those in 2001. All cause and cause specific SMRs were calculated using indirect standardisation using STATA-7. Cox regression was used to examine whether RF status predicted mortality in the RA cohort adjusting for age and gender. The Cox model's proportional hazards assumptions were tested graphically using the stphplot command in STATA-7. SMRs for this prevalent RA subgroup were calculated for all cause, CVD, IHD and MI mortality using the Stockport population mortality rates for these years.
CARDIOVASCULAR ADMISSIONS STUDY
Patients and methods
RESULTS
Mortality study
Date of birth, gender, year of diagnosis and rheumatoid factor status at diagnosis were recorded for 1008 of the 1010 patients. There were 729 (72%) women and median age at diagnosis was 60.4 years [IQR 50.4, 69.6] ( Table 1 ).
An attempt was made to validate the consultant diagnosis of RA. The medical records of 20 patients, selected randomly from the Stockport RA register, were reviewed and 18 patients met ACR classification criteria for RA. There was insufficient clinical information recorded to classify 2 patients.
The 979 (97 %) patients matched by ONS were used in the initial mortality analysis. The median follow up period was 11. Cause of death Cardiovascular disease was the most frequent cause of death (Table 1) , responsible for 48% of female and 44% of male deaths. Ischaemic heart disease (IHD) was recorded as the main cause of death in 125 (26%) cases and the main cause of death was ascribed to acute myocardial infarction (MI) in 72 (15%) cases (Table 2) .
Rheumatoid arthritis was identified as the underlying cause in only 36 (7.6%) deaths and was recorded anywhere on the death certificates of 44 (9%) patients. Standardised mortality ratios Both male and female RA patients had higher than expected mortality rates (Table 3) Mortality rates from all CVD causes in women were approximately twice that expected (SMR 1.93 (95%CI 1.65, 2.26) with a more modest increase being observed in male RA patients (SMR 1.36 (95%CI 1.04, 1.75). The SMRs for IHD were raised in both men and women and female RA patients had higher mortality rates from MI. In female RA patients 77 (51%) of the 149 excess deaths were due to CVD and 40 (27%) of the excess deaths were from IHD. Cardiovascular deaths were responsible for 38% of the 44 male excess deaths and 13 of the male excess deaths (29%) were from IHD. Mortality from respiratory causes was increased in both male and female RA patients and 36 respiratory deaths were coded as being due to pneumonia, 7 deaths due to interstitial lung disease, 1 death from asthma and the remaining respiratory deaths were from chronic obstructive airways disease. The number of deaths from neoplasia was not significantly different from that seen in the general population. 
Standardised admission ratios
The SAR for CVD was not raised in either males or females (Table 6 ). There were only a small number of admissions with IHD & MI.There were no significant increases in CVD SARs for seropositive RA patients (female seropositive patients SAR 1.10 (95% CI 0.54, 2.10); male seropositive patients SAR 1.44 (95% CI 0.95, 3.32)). Standardised mortality ratios in the admissions cohort There were 182 deaths in this group of 515 prevalent RA patients with 100 deaths being due to CVD causes (Table 7) . Cardiovascular mortality was significantly increased in both male (SMR 2.40; 95% CI 1.64, 3.39) and female (SMR 2.77; 95% CI 2.15, 3.51) patients. Women and seropositive patients had higher SMRs. Mortality from IHD was also increased in both sexes, but was more marked in women and seropositive patients. Mortality rates from MI were significantly increased in women. Approximately 15% of all deaths in this cohort were attributed to acute MI. There were more excess deaths from CVD than there were excess CVD admissions. Only 42 of the 100 patients in the RA cohort who died from CVD had any prior CVD admissions during the follow-up period. 
DISCUSSION
These studies have demonstrated that all cause and cardiovascular mortality is still increased in RA patients in the UK with an onset of disease in the 1980s and 1990s. Mortality was higher in, but not confined to, those patients who were RF positive at baseline. It seems likely that the absence of excess mortality described in other recent studies of patients with early RA may be attributed to aggressive disease control in these patients (7) (8) (9) . They were conducted in the context of early arthritis clinics where patients might experience early treatment with DMARDs. By contrast the Stockport RA cohort was managed in routine rheumatology outpatients and many were followed up in primary care.
Other studies have also observed a greater excess mortality in female than male RA patients (27;28) . This gender difference may be deceptive, in that population rates of CVD are lower in women than in men. Thus if RA had the same impact in men and women with respect to CVD, one would expect higher SMRs for women given the lower number of expected cases in the denominator.
In the prevalent RA cohort CVD admission rates were not increased, despite CVD mortality rates being twice those observed in the general population. One possible explanation could be that RA patients are less likely to experience multiple CVD admissions than the general population. Of the RA patients admitted to hospital, 70% had only one CVD admission during the 8 years of follow-up. This situation might occur if RA patients were more likely to die after or during their first CVD admission. If RA patients are less likely to experience or interpret significant angina symptoms they would be less likely to present at secondary care for treatment. This may lead to increased rates of unrecognised myocardial infarction and sudden cardiac death (19) . During the period of this study 34 (52%) of the RA patients, identified as having CVD admissions, died after their first CVD admission. Unfortunately, the number of first CVD admissions for the general population was not available. Therefore, it was not possible to compare the number of first CVD events in the RA cohort and the general population.
The study of respiratory outcomes was not one of the main aims of this study. However, We observed increased respiratory mortality rates in the RA patients and seropositive disease was a predictor of respiratory death after adjusting for age and gender. Possible explanations for the increased respiratory mortality include: 1) respiratory complications of RA, although only a small number of deaths were due to interstitial lung disease, or 2) the effects of cigarette smoking, which is identified as a risk factor for RA and seropositive disease (29). We were not able to examine associations between smoking and mortality in this study.
A strength of this study is that it was able to identify hospital admissions throughout the country for both the RA cohort and the local population controls.
The study has a number of limitations. Firstly, inclusion on the RA register was based on consultant diagnosis rather than application of the 1987 ACR classification criteria for RA (30) . Whilst this method lends a degree of external validity, as a consultant rheumatologist made the clinical diagnosis of RA, which reflects common rheumatological practice, it may have introduced misclassification bias. It is likely that simply using a consultant diagnosis of RA will have included patients with inflammatory polyarthritis who did not meet 4 out of 7 of the ACR classification criteria. These patients might be expected to have milder disease and therefore make it more difficult to detect an association with increased CVD mortality.
Baseline data on disease severity and disability were not collected. Nor was information on smoking, social history, or comorbid conditions recorded. Opportunities to look for predictors of mortality within the cohort were therefore limited.
This study relies on death certificate data for the main cause of death and hospital episode statistics for the main cause of admission. There are several limitations that can give rise to inaccuracies in mortality (31;32) and admission data (33;34) . Although it seems that the accuracy of coding for specific admission diagnoses has improved over recent years (35) . However, as population mortality and admission data are subject to the same inaccuracies it is unlikely that this will have introduced significant bias. Conversely if CVD is more likely to on 17 April 2008 ard.bmj.com Downloaded from remain clinically silent in RA it is likely that CVD diagnoses will be recorded less frequently as the primary cause of admission in this group. This may explain the similar rates of CVD admissions observed in this study. As described by others, RA was recorded infrequently on the death certificates of these patients (36;37).
In summary, patients who have developed RA in the last two decades continue to experience excess cardiovascular mortality in the 21 st century. This excess cardiovascular mortality is not reflected by an increased CVD admission rate. This may be due to high mortality during the first event or a failure to diagnose CVD before death.
